Rituximab treatment in lupus nephritis - Where do we stand?

Lupus

Volumn 22, Issue 4, 2013, Pages 381-389

  Gunnarsson, I ^a   Jonsdottir, T ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

antiCD20; lupus nephritis; rituximab; Systemic Lupus Erythematosus; treatment

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; RITUXIMAB;

CLINICAL PROTOCOL; DRUG MEGADOSE; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGISTER; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LUPUS NEPHRITIS; OFF-LABEL USE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875935404     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312471574     Document Type: Review

References (25)

1. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 ; 46: 2673-2677
2. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol. 2004 ; 33: 423-427
3. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005 ; 52: 501-513
4. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide- resistant proliferative lupus nephritis. Arthritis Rheum. 2007 ; 56: 1263-1272
5. Melander C, Sallee M, Trolliet P, et al. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009 ; 4: 579-587
6. Li EK, Tam LS, Zhu TY, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology (Oxford). 2009 ; 48: 892-898
7. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study. Nephrol Dial Transplant. 2009 ; 24: 2157-2160
8. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009 ; 24: 3717-3723
9. Jonsdottir T, Sundelin B, Welin Henriksson E, van Vollenhoven RF, Gunnarsson I. Rituximab-treated membranous lupus nephritis: Clinical outcome and effects on electron dense deposits. Ann Rheum Dis. 2001 ; 70: 1172-1173
10. Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Long term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008 ; 35: 826-833
11. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 2009 ; 61: 482-487
12. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2013 ; 25: 3586-3592
13. Arce-Salinas CA, Rodriguez-Garcia F, Gomez-Vargas JI. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int. 2012 ; 32: 1245-1249
14. Moroni G, Gallelli B, Sinico RA, et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: A clinical observational study. Ann Rheum Dis. 2012 ; 71: 1751-1752
15. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2013 ; 62: 2458-2466
16. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev. 2012 ; 11: 357-364
17. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2013 ; 28: 468-476
18. Jonsdottir T, Gunnarsson I, Mourao AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2013 ; 49: 1502-1504
19. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 ; 64: 1215-1226
20. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 ; 15: 241-250
21. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997 ; 51: 1188-1195
22. Mok MY, Li WL. Do Asian patients have worse lupus?. Lupus. 2013 ; 19: 1384-1390
23. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of Ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): Results from the randomized, double-blind phase III BELONG study. Arthritis Rheum. 2013 ; 62: 1455-1455
24. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228
25. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2013 ; 62: 222-233